Annexon, Inc.

74 articles about Annexon, Inc.

• Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

  11/9/2021

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced recent highlights and reported third quarter 2021 financial results.

• 

  BioSpace Movers & Shakers, Oct. 8

  10/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer

  10/4/2021

  Annexon, Inc., a clinical-stage company developing a new class of medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the appointment of Ted Yednock, Ph.D., as chief innovation officer, and the appointment of Larry Mattheakis, Ph.D., as chief scientific officer.

• Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference

  9/23/2021

  Annexon, Inc. announced that Douglas Love, Esq., President & Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 12:40 p.m. ET.

• Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event

  9/20/2021

  Annexon, Inc. announced that the company will host its second virtual C1q Series event on Monday, September 27, 2021, at 10:00 a.m. ET, to discuss its neurodegeneration franchise.

• Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update

  8/16/2021

  Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), Annexon, a clinical-stage biopharmaceutical company developing a class of new complement medicines for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced second quarter 2021 financial results and provided a mid-year business update.

• Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

  7/22/2021

  Annexon to host virtual autoimmune R&D event with leading experts on Wednesday, July 28, at 10:30 a.m. ET 

• Annexon to Present at the Raymond James Human Health Innovation Conference

  6/16/2021

  Today,  Annexon, Inc. announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the virtual Raymond James Human Health Innovation Conference on June 23rd, 2021 at 1:20 p.m.

• Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results

  5/17/2021

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced first quarter 2021 financial results and business highlights.

• Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference

  5/5/2021

  Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the Bank of America Securities 2021 Virtual Healthcare Conference

• Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights

  3/25/2021

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced fourth quarter and full-year 2020 financial results and business highlights.

• Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy

  3/1/2021

  Annexon, Inc., a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced that patient dosing has begun in its Phase 2 ARCHER study of its anti-C1q therapy, ANX007, to treat Geographic Atrophy.

• Annexon Welcomes William H. Carson, M.D. to the Board of DirectorsThomas G. Wiggans appointed Chairman

  2/8/2021

  Annexon, Inc.  (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced the appointment of William H. Carson, M.D. to its board of directors.

• Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics

  1/12/2021

  Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today highlights recent achievements and outlines expected key 2021 milestones at the J.P. Morgan 39 th Annual Healthcare Conference, held virtually. “2020 was a foundational year for A

• Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference

  1/5/2021

  Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced that a corporate update will be presented at the 39 th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 4:30pm ET. A live webcast of the event can be acce

• Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome

  12/21/2020

  Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the brain, body, and eye, announced that patient dosing has started in a Phase 2/3 clinical study of full-length monoclonal antibody, ANX005, to treat Guillain-Barré Syndrome (GBS).

• Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights

  11/16/2020

  Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye, today announced third quarter 2020 financial results and recent business highlights.

• Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

  11/12/2020

  First patient dosed in Phase 2 study of ANX005 C1q targeted mAb

• Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

  9/8/2020

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced second quarter 2020 financial results and recent highlights.

• Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer

  7/30/2020

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the appointment of Michael Overdorf as Chief Business Officer. “I’m pleased to welcome Michael to our organization as we look to leverage his expertise across the organization, and in particular with regard to our